

In re application of:

WILLIAMS et al.

Appl. No. 09/839,946

Filed: April 19, 2001

For:

**PEG-Urate Oxidase Conjugates** 

and Use Thereof

Confirmation No. 5256

Art Unit: 165

Examiner: Saidha, T.

Atty. Docket: 2057.0090003/JAG/BJD

## Fourth Supplemental Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on December 11, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Fourth Supplemental Information Disclosure Statement is being filed before the mailing of a final action on the merits or a Notice of Allowance, but after the mailing of a first action on the merits, in the captioned application. In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Attorney for Applicants Registration No. 42,473

Date: De C. 16, 7003

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

::ODMA\MHODMA\SKGF\_DC1;210227;1 SKGF Rev. 8/28/02 mac

Page 1 of 1

	OIPE						
	JUL 0 6 2004 22						
FORM	PTO-1449						

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. APPLICATION NO. 2057.0090003/JAG/BJD 09/839,946						
APPLICANT Williams et al.						
FILING DATE April 19, 2001	GROUP 1652					

			<del>=====================================</del>	U.S. PATI	ENT DOCUMENTS				
EXAMINER	Γ	Т				T	T		
INITIAL		DOC	CUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE	
	AA	T				1			
	AB								
	AC						T		
	AD	1							
	AE								
	AF								
	AG								
	АН								
	AI								
	AJ								
	AK								
				FOREIGN PA	TENT DOCUMENTS				
EXAMINER									
INITIAL	<u> </u>	DOCU	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
	AL					'		Yes No	
	AM					<u> </u>		Yes No	
	AN							Yes No	
	AO							Yes No	
								Yes	
-	AP				= =			. No	
· · · · · · · · · · · · · · · · · · ·			THER (Including	3 Author, Titi	le, Date, Pertinent Page	s, etc.)			
·	AR	20	Alvares, K., et al., "The nucleotide sequence of a full length cDNA clone encoding rat liver urate oxidase," Biochem. Biophys. Res. Commun. 158:991-995 (1989).						
	AS							,	
	TA								
EXAMINER					1	DATE CONSI	DERED		

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.







Due Date:

n/a

**Art Unit:** 

1652

Examiner:

Saidha, T.

Docket:

2057.0090003

Filed:

Applicant:

09/839,946

Atty:

JAG/BJD

April 19, 2001

Williams et al.

PEG-Urate Oxidase Conjugates and Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

SKGF Cover Letter:

Application No.:

Credit Card Payment Form (PTO-2038) in the amount of \$130.00 to cover the appropriate fees; 2.

PTO Fee Transmittal (PTO/SB/17); 3.

Fourth Supplemental Information Disclosure Statement;

One page of Form PTO-1449 citing one document;

6. A copy of the cited document (AR20); and

7. One (1) return postcard.

Please Date Stamp And Return To Our Courier

::ODMA\MHODMA\SKGF\_DC1;210377;1